Evidence map›Paper›PMID 22326768›Full record

ArticleArtificial intelligence in medicine2012

Pathway-based identification of a smoking associated 6-gene signature predictive of lung cancer risk and survival.

Nancy Lan Guo, Ying-Wooi Wan

Abstract read
In one paragraph

Article in Artificial intelligence in medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Nancy Lan GuoDepartment of Community Medicine, West Virginia University, Morgantown, WV 26506, USA. lguo@hsc.wvu.edu
Ying-Wooi Wan
West Virginia University · US

Funding

THE ROLE OF HEF1 PROTEIN IN INVASION OF METASTATIC BREAST CANCERP20RR016440 · NCRR · WEST VIRGINIA UNIVERSITY · PI CUFF, CHRISTOPHER F · 2001 to 2010
$22.8M
A Novel Computational Framework for Individualized Clinical Decision-MakingR01LM009500 · NLM · WEST VIRGINIA UNIVERSITY · PI GUO, NANCY LAN · 2008 to 2010
$987k
A Novel Computational Framework for individualized clinical decision-makingR56LM009500 · NLM · WEST VIRGINIA UNIVERSITY · PI GUO, NANCY LAN · 2012 to 2013
$499k
NCRR NIH HHS P20 RR016440NCRR NIH HHS P20RR16440NLM NIH HHS R01 LM009500NLM NIH HHS R01LM009500NLM NIH HHS R56 LM009500PHS HHS P2016477
6 · The paper itself

Abstract

objectiveSmoking is a prominent risk factor for lung cancer. However, it is not an established prognostic factor for lung cancer in clinics. To date, no gene test is available for diagnostic screening of lung cancer risk or prognostication of clinical outcome in smokers. This study sought to identify a smoking associated gene signature in order to provide a more precise diagnosis and prognosis of lung cancer in smokers. METHODS AND MATERIALS: An implication network based methodology was used to identify biomarkers by modeling crosstalk with major lung cancer signaling pathways. Specifically, the methodology contains the following steps: (1) identifying genes significantly associated with lung cancer survival; (2) selecting candidate genes which are differentially expressed in smokers versus non-smokers from the survival genes identified in Step 1; (3) from these candidate genes, constructing gene coexpression networks based on prediction logic for the smoker group and the non-smoker group, respectively; (4) identifying smoking-mediated differential components, i.e., the unique gene coexpression patterns specific to each group; and (5) from the differential components, identifying genes directly co-expressed with major lung cancer signaling hallmarks.

resultsA smoking-associated 6-gene signature was identified for prognosis of lung cancer from a training cohort (n=256). The 6-gene signature could separate lung cancer patients into two risk groups with distinct post-operative survival (log-rank P<0.04, Kaplan-Meier analyses) in three independent cohorts (n=427). The expression-defined prognostic prediction is strongly related to smoking association and smoking cessation (P<0.02; Pearson's Chi-squared tests). The 6-gene signature is an accurate prognostic factor (hazard ratio=1.89, 95% CI: [1.04, 3.43]) compared to common clinical covariates in multivariate Cox analysis. The 6-gene signature also provides an accurate diagnosis of lung cancer with an overall accuracy of 73% in a cohort of smokers (n=164). The coexpression patterns derived from the implication networks were validated with interactions reported in the literature retrieved with STRING8, Ingenuity Pathway Analysis, and Pathway Studio.

conclusionsThe pathway-based approach identified a smoking-associated 6-gene signature that predicts lung cancer risk and survival. This gene signature has potential clinical implications in the diagnosis and prognosis of lung cancer in smokers.

Indexed as

Gene Regulatory NetworksAdenocarcinomaAdenocarcinoma of LungAgedCohort StudiesGene Expression ProfilingGenetic MarkersGenetic Predisposition to DiseaseHumansKaplan-Meier EstimateLung NeoplasmsMaleMiddle AgedMultivariate AnalysisOligonucleotide Array Sequence AnalysisPrognosisGenetic Markers

Identifiers

PMID22326768
PMCPMC3351561
OpenAlexW2052810243

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.